LKFT · NASDAQ
Lakefront Biotherapeutics NV (LKFT) Stock Price & Fundamentals
Lakefront Biotherapeutics NV (LKFT) closed at $432.48 on Oct 9, 2026, down 1.38% from the previous close of $438.55.
Share price, past year
1Y +0.53%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $432.48 |
| Sep 30, 2026 | $429.20 |
| Aug 31, 2026 | $411.40 |
| Jul 31, 2026 | $390.51 |
| Jun 30, 2026 | $374.39 |
| May 29, 2026 | $401.73 |
| Apr 30, 2026 | $409.48 |
| Mar 31, 2026 | $409.60 |
| Feb 27, 2026 | $417.69 |
| Jan 30, 2026 | $413.21 |
| Dec 31, 2025 | $412.27 |
| Nov 28, 2025 | $447.36 |
| Oct 31, 2025 | $456.10 |
Key statistics
- Market cap
- —
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- —
- Shares outstanding
- 65.9M
- Dividend yield
- —
- 52-week range
- $363.60 – $475.48
Market cap, P/E and dividend yield aren't shown for Lakefront Biotherapeutics NV yet: its SEC filings count its ordinary shares, which can differ from the shares traded in the US, and report in euros.
Financials
Lakefront Biotherapeutics NV reported revenue of €1.11B for fiscal 2025, up 303.50% from fiscal 2024.
Figures are in euros (EUR), as Lakefront Biotherapeutics NV reports them to the SEC.
Lakefront Biotherapeutics NV earned net income of €320.88M in fiscal 2025, a net margin of 28.9%.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | €1.11B | +303.5% | €320.88M | 28.9% | €4.87 | −€271.16M |
| FY2024ended Dec 31, 2024 | €275.65M | +15.0% | €74.08M | 26.9% | €1.12 | −€336.75M |
| FY2023ended Dec 31, 2023 | €239.72M | −0.6% | €211.70M | 88.3% | €3.21 | −€424.68M |
| FY2022ended Dec 31, 2022 | €241.25M | +2.9% | −€217.99M | −90.4% | −€3.32 | −€527.93M |
| FY2021ended Dec 31, 2021 | €234.38M | −51.0% | −€103.23M | −44.0% | −€1.58 | −€558.03M |
| FY2020ended Dec 31, 2020 | €478.05M | −42.7% | −€305.44M | −63.9% | −€4.69 | −€469.86M |
| FY2019ended Dec 31, 2019 | €834.90M | +199.6% | €149.85M | 18.0% | €2.49 | €3.19B |
| FY2018ended Dec 31, 2018 | €278.67M | +119.3% | −€29.26M | −10.5% | −€0.56 | −€152.86M |
| FY2017ended Dec 31, 2017 | €127.09M | −1.9% | −€115.70M | −91.0% | −€2.34 | −€152.34M |
| FY2016ended Dec 31, 2016 | €129.52M | — | €54.01M | 41.7% | €1.14 | €234.95M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2021ended Jun 30, 2021 | €139.77M | −€64.33M | — |
| Q2 FY2020ended Jun 30, 2020 | €99.59M | −€115.04M | — |
| Q2 FY2019ended Jun 30, 2019 | €58.74M | −€47.25M | — |
| Q2 FY2018ended Jun 30, 2018 | €49.68M | −€21.77M | — |
| Q2 FY2017ended Jun 30, 2017 | €26.93M | −€35.64M | — |
Company profile
- Name
- Lakefront Biotherapeutics NV
- Ticker
- LKFT
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- Schalienhoevedreef 20t, 2800 Mechelen
- Incorporated in
- C9
- SEC CIK
- 0001421876
Recent SEC filings
- Mar 26, 2026
- Mar 27, 2025
- Mar 28, 2024
- Mar 23, 2023
- Mar 24, 2022
- Mar 25, 2021
- Mar 27, 2020
- Mar 29, 2019
Frequently asked questions
What is Lakefront Biotherapeutics NV's stock price?
Lakefront Biotherapeutics NV (LKFT) closed at $432.48 on Oct 9, 2026, down 1.38% from the previous close of $438.55.
How much revenue does Lakefront Biotherapeutics NV make?
Lakefront Biotherapeutics NV reported revenue of €1.11B for fiscal 2025, up 303.50% from fiscal 2024.
Sources and methodology
Fundamentals come from Lakefront Biotherapeutics NV's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures